Patents Examined by Lauren Wells
  • Patent number: 12157739
    Abstract: The present invention relates to hypoxanthine compound or a pharmaceutically acceptable salt thereof. The compounds of the present invention or pharmaceutically acceptable salts thereof have prolyl hydroxylase inhibitory effect and are useful as agents for the treatment of inflammatory bowel diseases such as ulcerative colitis and the like. In an embodiment, the present invention relates to a method for treating an inflammatory bowel disease, comprising administering a necessary amount of a pharmaceutical composition containing hypoxanthine compound or a pharmaceutically acceptable salt thereof, and pharmaceutical additive to a patient.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: December 3, 2024
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Yasushi Takigawa, Yusuke Kawabe, Haruka Ohtsuki, Kyosuke Nakamura
  • Patent number: 12157735
    Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: December 3, 2024
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
  • Patent number: 12109263
    Abstract: Small molecule integrin agonists or integrin activating compounds including at least one di-alkylaryl amine end group and at least one alkyl or alkenoxy linking group including at least one protonatable moiety, wherein the compounds enhance vaccine efficacies, enhance adoptive cell therapy efficacies, enhance immunotherapy efficacies, enhance therapeutic antibody therapy efficacies, enhance checkpoint inhibitor therapy efficacies, enhance effector cell therapy efficacies, and enhanced cell based transplant efficacies and wherein at protonatable moiety either protonate at biological pHs or bears a charge with associated pharmaceutically acceptable counterion making the compound water soluble to improve bioavailability and methods for making and using same.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: October 8, 2024
    Inventor: Robert W Strozier
  • Patent number: 12103915
    Abstract: The disclosure provides for compounds and methods for modulating or inhibiting TEAD. Further provided herein are pharmaceutical compositions comprising the TEAD inhibitors and methods of treatment using the TEAD inhibitors or the pharmaceutical compositions.
    Type: Grant
    Filed: December 5, 2023
    Date of Patent: October 1, 2024
    Assignee: INSILICO MEDICINE IP LIMITED
    Inventors: Xiao Ding, Jinxin Liu, Feng Ren, Jianfei Wan, Wei Zhu
  • Patent number: 12060345
    Abstract: The present application provides a method of preparing 4-[3-(3-[(cyclopropylamino)methyl]azetidine-1-carbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one, or a pharmaceutically acceptable salt thereof, intermediates in the preparation thereof, methods of preparing the intermediates, and compositions and products comprising 4-[3-(3-[(cyclopropylamino)methyl]azetidine-1-carbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one made from the methods that result in high purity and yield.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: August 13, 2024
    Assignee: IDIENCE CO., LTD.
    Inventors: Keuncheol Ryu, Seoktaek Lee, Hanna Seo, Hyeran Yang, Wonje Seong, Jinyoung Yoon
  • Patent number: 12054493
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: August 6, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Xuri Gao, Wei Li, Hui Cao, Meizhong Jin, Jorden Kass, Xiaowen Peng, Yat Sun Or
  • Patent number: 12053446
    Abstract: Oseltamivir is used as active agent to treat a hearing impairment and to prevent a hearing impairment, and a method of treating and/or preventing hearing impairments or disorders using Oseltamivir are disclosed. Oseltamivir exhibits excellent protection against noise-induced hearing loss and against cisplatin-induced hearing loss.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: August 6, 2024
    Assignees: Ting Therapeutics LLC, St Jude Children's Research Hospital
    Inventors: Tal Teitz, Jian Zuo, Taosheng Chen
  • Patent number: 12049464
    Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.
    Type: Grant
    Filed: September 1, 2022
    Date of Patent: July 30, 2024
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
  • Patent number: 12049463
    Abstract: The present disclosure relates to a novel crystalline form of Tolebrutinib (hereinafter referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing BTK inhibitor drugs and drugs for treating multiple sclerosis.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: July 30, 2024
    Assignee: Genzyme Corporation
    Inventors: Minhua Chen, Jiaming Shi
  • Patent number: 12035739
    Abstract: A nutritional supplement is described that is useful in combination with radiotherapy to reduce the growth of tumor stem cells. The nutritional supplement includes selenium and fish oil, and has been also found to be effective in reducing negative side effects of concurrent radiotherapy, including inflammation, weight loss, muscle wasting, neutropenia, and loss of cells from the lining of the gut.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: July 16, 2024
    Inventor: Houn Simon Hsia
  • Patent number: 12018015
    Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: June 25, 2024
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Cheng Liu, Jerome Deval, David McGowan
  • Patent number: 12016857
    Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: June 25, 2024
    Assignees: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LTD.
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Patent number: 11998554
    Abstract: The present invention regards a composition comprising lipoic acid, or an acceptable pharmaceutical or food grade salt thereof or a derivative thereof, and a vitamin D, preferably vitamin D3 and/or vitamin D2, for use in a method for the treatment of neurodegenerative diseases and/or for the treatment of peripheral neuropathies.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: June 4, 2024
    Assignee: URIACH ITALY S.R.L.
    Inventor: Lorenzo Secondini
  • Patent number: 11986483
    Abstract: The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and/or clotrimazole and dexamethasone.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: May 21, 2024
    Assignee: Dechra Veterinary Products, LLC
    Inventors: Douglas I. Hepler, Gail L. Dempsey, Dorothea A. Erxleben, Neil E. Paulsen
  • Patent number: 11974969
    Abstract: The invention provides an artificially synthesized single sphingosine lipid and use of delivering a nucleic acid thereof.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: May 7, 2024
    Assignee: INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Chengyu Jiang, Yuhao Qin, Xiaoyun Li, Cong Zhang
  • Patent number: 11970447
    Abstract: Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: April 30, 2024
    Assignee: CANNA-CHEMISTRIES LLC
    Inventors: Nate Schultheiss, Nico Setiawan, Lisa M. McCracken, David Jonaitis
  • Patent number: 11963967
    Abstract: Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: April 23, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Thomas P. Stratton, Peiyuan Wang
  • Patent number: 11925623
    Abstract: The invention provides compositions and methods for treating conditions associated with decreased activity of hydrogen sulfide.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: March 12, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Robert Vince, Swati Sudhakar More
  • Patent number: 11925609
    Abstract: Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise ablation of a region of the small intestine in the subject, in particular ablation of a region of the duodenum. The ablation may be a mechanical, electrical, thermal, radiative, or chemical ablation and may in some cases target a sensory nerve. The methods may, in some cases, comprise the step of administering an active agent directly to the small intestine in the subject, in particular administering the active agent directly to the duodenum.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: March 12, 2024
    Inventors: Pankaj Pasricha, Liansheng Liu
  • Patent number: 11912699
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: February 27, 2024
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Michael Berlin, Angela M. Cacace, Julian T. Chandler